Experience the DARZALEX® difference
A treatment supported by many years of real-world clinical use
Talk to your doctor about the possibility of a treatment regimen based on DARZALEX FASPRO® or DARZALEX®.
Established Treatment
Combined, DARZALEX FASPRO® and DARZALEX® have a long legacy of results, leadership, and proven effectiveness since the initial approval of DARZALEX® in 2015. DARZALEX FASPRO® was approved in 2020 and has been shown to be effective in regimens for people with newly diagnosed multiple myeloma and people who have relapsed with prior treatment.
Standard Treatment
Since it was approved in 2015, DARZALEX® has become a standard of care in multiple myeloma treatment. And more than 682,000 people have been given a DARZALEX®- or DARZALEX FASPRO®-based treatment.†
*According to IQVIA claims data from December 2024 through July 2025.
†As of June 30, 2025. Estimate based on unit shipments.
DARZALEX FASPRO® and DARZALEX® dosing and administration
Once-Monthly Dosing
Depending on transplant eligibility, people with newly diagnosed multiple myeloma have the chance to transition to once-monthly dosing in under 6 months when they are treated with DARZALEX FASPRO® + VRd or DARZALEX® + Rd.*
Delivered via Injection
DARZALEX FASPRO® is given in a ~3- to 5-minute injection under the skin. And with 5 years of administering DARZALEX FASPRO®, nurses and healthcare providers are familiar with giving the injection.
*Your doctor will determine your transplant eligibility.